We are delighted and honoured that Callavid® has been named in this National Institute for Health and Care Research (NIHR) news story highlighting the role NIHR is playing in improving outcomes for women through the UK Government’s revised Women’s Health Strategy. 🇬🇧

As NIHR notes:
“NIHR is funding ‘Callavid’ which if approved would be the world’s first drug-device combination to treat threatened miscarriage.”

We are proud to be contributing to the growing momentum behind better innovation and outcomes in women’s health! 💪

original article here: https://www.nihr.ac.uk/news/womens-health-strategy-renewal-important-step-forward